PSYCHOEMOTIONAL STATE OF PATIENTS WITH CORONARY HEART DISEASE AND CHRONIC KIDNEY DISEASE: THE ROLE OF LIPID-LOWERING THERAPY WITH EZETIMIBE
Main Article Content
Abstract
This article examines the psychoemotional state of patients suffering from coronary heart disease (CHD) and chronic kidney disease (CKD) and evaluates the impact of lipid-lowering therapy with ezetimibe on their emotional well-being. The relationship between lipid metabolism disorders, systemic inflammation, and the development of depressive and anxiety symptoms is explored. Special attention is given to the therapeutic potential of ezetimibe in not only improving lipid profiles but also contributing to the stabilization of psychoemotional status in this vulnerable group. Clinical findings support the hypothesis that comprehensive lipid management is integral to both physical and psychological health outcomes in CHD and CKD patients.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
1.Grundy, S. M., Stone, N. J., Bailey, A. L. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol // Journal of the American College of Cardiology. – 2019. – Vol. 73, № 24. – P. e285–e350.
2.Cannon, C. P., Blazing, M. A., Giugliano, R. P. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes // New England Journal of Medicine. – 2015. – Vol. 372, № 25. – P. 2387–2397.
3.Baigent, C., Keech, A., Kearney, P. M. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins // The Lancet. – 2005. – Vol. 366, № 9493. – P. 1267–1278.
4.Libby, P. Inflammation in atherosclerosis // Nature. – 2002. – Vol. 420, № 6917. – P. 868–874.